HOLX vs. IDXX: Which Stock Is the Better Value Option?

Zacks research identifies Hologic (HOLX) as the superior value option over Idexx Laboratories (IDXX) in the Medical-Instruments sector, driven by HOLX's Zacks Rank #2 (Buy) and significantly lower valuation multiples. HOLX exhibits a forward P/E of 15.95, PEG of 2.45, and P/B of 3.1, indicating a strong value profile. This contrasts with IDXX's Zacks Rank #3 (Hold) and higher P/E of 50.91, PEG of 4.16, and P/B of 35.04, positioning HOLX as a more attractive prospect for value investors.

Analysis

A comparative fundamental analysis of Hologic (HOLX) and Idexx Laboratories (IDXX) within the Medical-Instruments sector identifies a significant valuation disparity. Hologic is positioned as the more attractive value investment, supported by a Zacks Rank of #2 (Buy), which indicates a trend of positive earnings estimate revisions. In contrast, Idexx Laboratories holds a Zacks Rank of #3 (Hold). The valuation gap is stark across key metrics: HOLX trades at a forward P/E of 15.95, while IDXX has a much higher multiple of 50.91. This is further substantiated by their PEG ratios, with HOLX at 2.45 versus IDXX at 4.16, suggesting HOLX is more reasonably priced relative to its expected earnings growth. The Price-to-Book (P/B) ratio highlights an even more dramatic difference, with HOLX at 3.1 compared to IDXX's 35.04. These quantitative factors culminate in HOLX earning a 'B' for its Zacks Value grade, while IDXX receives a 'D', reinforcing the conclusion that HOLX presents a superior value profile based on current metrics.

Key Decisions for Investors

• Value-focused investors should consider Hologic (HOLX) as a potentially undervalued opportunity, given its strong 'Buy' rank, positive earnings outlook, and significant discount on P/E, PEG, and P/B multiples compared to its peer.
• Investors holding Idexx Laboratories (IDXX) should scrutinize its high valuation (forward P/E of 50.91, P/B of 35.04), as this premium pricing may pose a risk in the event of any slowdown in growth or negative earnings surprises.
• For relative value strategies, the pronounced valuation gap between the two firms could suggest a potential pair trade, favoring a long position in HOLX against a short position in IDXX, pending further due diligence on company-specific catalysts.